BRPI0518101A - métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso - Google Patents

métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso

Info

Publication number
BRPI0518101A
BRPI0518101A BRPI0518101-1A BRPI0518101A BRPI0518101A BR PI0518101 A BRPI0518101 A BR PI0518101A BR PI0518101 A BRPI0518101 A BR PI0518101A BR PI0518101 A BRPI0518101 A BR PI0518101A
Authority
BR
Brazil
Prior art keywords
compositions
nanoparticulate
present
synthesis
nanoparticulate compositions
Prior art date
Application number
BRPI0518101-1A
Other languages
English (en)
Inventor
Trevor Payne
Felix Meiser
Almar Postma
Raffaele Cammarano
Frank Caruso
James Williams
Paul Mccormick
Aaron Dodd
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004907377A external-priority patent/AU2004907377A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of BRPI0518101A publication Critical patent/BRPI0518101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

MéTODOS DE PRODUçãO E SìNTESE DE COMPOSIçõES NANOPARTICULADAS. Trata-se a presente invenção de composições m icroestruturais melhoradas de nanocompósitos terapeuticamente ativos, que incluem composições nanoparticuladas e preparações nanoparticuladas. As modalidades preferidas da presente invenção incluem composições nanoparticuladas, que compreendem nanopartículas de um agente terapeuticamente ativo dispersas em uma matriz carreadora. A presente invenção também se refere a um método para o preparo das ditas composições nanoparticuladas e preparações nanoparticuladas, por meio do uso da sintese mecanoquímica no estado sólido. Adicionalmente, a presente invenção também se refere aos produtos terapêuticos produzidos por meio do uso das ditas composições nanoparticuladas, bem como a métodos de tratamento, por meio do uso das ditas composições nanoparticuladas.
BRPI0518101-1A 2004-12-31 2005-12-30 métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso BRPI0518101A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004907377A AU2004907377A0 (en) 2004-12-31 Nano-Particle Composition(s) and Method for Synthesis Thereof
PCT/AU2005/001977 WO2006069419A1 (en) 2004-12-31 2005-12-30 Nanoparticle composition and methods for synthesis thereof

Publications (1)

Publication Number Publication Date
BRPI0518101A true BRPI0518101A (pt) 2008-10-28

Family

ID=36614419

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518101-1A BRPI0518101A (pt) 2004-12-31 2005-12-30 métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso

Country Status (10)

Country Link
US (3) US20090028948A1 (pt)
EP (1) EP1830824B1 (pt)
JP (2) JP6091041B2 (pt)
CN (2) CN101094659A (pt)
BR (1) BRPI0518101A (pt)
CA (2) CA2858733C (pt)
IL (1) IL183843A (pt)
NZ (1) NZ555719A (pt)
WO (1) WO2006069419A1 (pt)
ZA (1) ZA200704613B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378233T3 (es) * 2004-09-21 2012-04-10 G & I Irtech S.L. Proceso y máquina para la aglomeración y/o secado de materiales en polvo usando radiación infrarroja
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
TWI564033B (zh) * 2006-06-30 2017-01-01 艾修提卡股份有限公司 製造奈米微粒形式生物活性化合物之方法
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP2009203102A (ja) * 2008-02-27 2009-09-10 Nagoya Institute Of Technology セラミックス粉体の固化方法及びセラミックス固化体
NZ722319A (en) * 2009-04-24 2018-01-26 Iceutica Pty Ltd A novel formulation of meloxicam
AU2014208310C1 (en) * 2009-04-24 2020-01-23 Iceutica Pty Ltd A Novel Formulation of Diclofenac
WO2010121320A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
CN104825396A (zh) * 2009-04-24 2015-08-12 伊休蒂卡有限公司 用于改善生物活性物质溶出度特征的方法
SG175767A1 (en) * 2009-04-24 2011-12-29 Iceutica Pty Ltd A novel formulation of naproxen
NZ595984A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
AU2014201967B2 (en) * 2009-04-24 2015-09-17 Iceutica Pty Ltd A Novel Formulation of Naproxen
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
KR101743847B1 (ko) 2009-04-24 2017-06-05 아이슈티카 피티와이 리미티드 신규 인도메타신 제제
KR101580656B1 (ko) 2009-04-24 2015-12-30 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
AU2010261510A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
US20120301498A1 (en) 2011-04-29 2012-11-29 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
JP6073545B2 (ja) * 2011-10-04 2017-02-01 横浜油脂工業株式会社 リグナン類含有微粒子及び組成物
WO2014168845A1 (en) * 2013-04-08 2014-10-16 Igdrasol Method of engineering nanoparticle
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
CN104624132B (zh) * 2013-11-07 2017-02-08 中国科学院化学研究所 环氧树脂自修复微胶囊及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
IL292574A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and preparations for attenuating immune responses in an antiviral transfer system
CN105241793B (zh) * 2015-09-07 2016-10-26 国家纳米科学中心 一种载药胶束形态粒径的测定方法
CA3013123A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
KR102061179B1 (ko) * 2016-11-09 2019-12-31 한밭대학교 산학협력단 고흡착성을 가진 고분자브러시 발포체 복합소재 및 이의 제조방법
WO2018142189A1 (en) * 2017-02-02 2018-08-09 Dukebox Sp. Z O. O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
JP2020510687A (ja) 2017-03-11 2020-04-09 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
DE102017108611A1 (de) * 2017-04-21 2018-10-25 Technische Universität Clausthal Energie-effizientes lösungsmittelfreies Verfahren zur Herstellung von Aminosäure-Metallchelaten
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
BR112020013750A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
DE102018000418A1 (de) 2018-01-20 2019-07-25 Bürkle Consulting Gmbh Mechanochemisches Verfahren zur Herstellung von von persistenten organischen Schadstoffen und anderen Organohalogenverbindungen freien Wertprodukten aus Abfällen von Kunststoffen und Kunststofflaminaten
CN108715442B (zh) * 2018-08-01 2021-11-12 广西零到壹科技有限责任公司 机械活化连续反应制备高纯磷酸锌的设备及其应用
US20210369720A1 (en) * 2018-11-02 2021-12-02 Rutgers, The State University Of New Jersey Synergistic composition having neuroprotective properties and methods of use thereof
DE102019006084A1 (de) 2019-02-12 2020-08-13 Elke Münch Mechanochemisches Verfahren

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
WO1994014503A1 (en) * 1992-12-18 1994-07-07 Technological Resources Pty. Limited Toxic material disposal
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
AUPP355798A0 (en) * 1998-05-15 1998-06-11 University Of Western Australia, The Process for the production of ultrafine powders
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP4541647B2 (ja) * 2000-11-20 2010-09-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
FI20010115A0 (fi) * 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20070071825A1 (en) * 2003-10-01 2007-03-29 Catherine Curdy Device and method for making particles
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.

Also Published As

Publication number Publication date
CN101094659A (zh) 2007-12-26
NZ555719A (en) 2010-11-26
US20180169028A1 (en) 2018-06-21
WO2006069419A1 (en) 2006-07-06
EP1830824A1 (en) 2007-09-12
CN104083342A (zh) 2014-10-08
CA2858733A1 (en) 2006-07-06
CA2858733C (en) 2017-12-19
IL183843A (en) 2017-01-31
JP2016106123A (ja) 2016-06-16
EP1830824B1 (en) 2016-01-13
IL183843A0 (en) 2007-10-31
EP1830824A4 (en) 2012-08-29
CA2593862C (en) 2014-10-21
JP2008526689A (ja) 2008-07-24
JP6091041B2 (ja) 2017-03-08
CA2593862A1 (en) 2006-07-06
ZA200704613B (en) 2008-05-28
US20200360294A1 (en) 2020-11-19
JP6113878B2 (ja) 2017-04-12
US20090028948A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
BRPI0908686B8 (pt) método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
PH12015501780A1 (en) Production of encapsulated nanoparticles at commercial scale
NO20075136L (no) Nye liposompreparater
MY159098A (en) Production of encapsulated nanoparticles at high volume fractions
NZ595987A (en) A novel formulation of diclofenac
CR11723A (es) Agente para tratar enfermedad
NZ595903A (en) A novel formulation of metaxalone
PH12016500746B1 (en) A novel formulation of meloxicam
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
MY159208A (en) A novel formulation of indomethacin
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
AR074406A1 (es) Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação
MD2975G2 (ro) Remediu sub formă de gel pentru tratamentul rozaceei
NZ710321A (en) Production of encapsulated nanoparticles at high volume fractions
PH12015501811A1 (en) Production of encapsulated nanoparticles at high volume fractions
BRPI0705599A2 (pt) nanopartÍculas biodegradÁveis para encapsulaÇço de ingredientes ativos, processo para sua obtenÇço, composiÇço compreendendo nanopartÍculas
CU20080122A7 (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]